Cryo-Cell International, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CCEL research report →
Range $8.5 – $8.5
Price Chart
About the company
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use.
- CEO
- David Portnoy
- IPO
- 1994
- Employees
- 74
- HQ
- Oldsmar, FL, US
Get TickerSpark's AI analysis on CCEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $31.28M
- P/E
- -13.19
- Fwd P/E
- 35.27
- PEG
- 0.59
- P/S
- 1.00
- P/B
- -1.76
- EV/EBITDA
- 68.70
- Div Yield
- 0.00%
- Gross Margin
- 77.34%
- Op Margin
- -0.33%
- Net Margin
- -7.92%
- ROE
- 14.18%
- ROIC
- -0.22%
Latest fiscal year · YoY change
- Revenue
- $31.57M-1.3%
- Gross Profit
- $24.19M+0.6%
- Op Income
- $4.84M
- Net Income
- $-2,429,385-704.2%
- EPS
- $-0.30-700.0%
- OCF Growth
- -8.9%
- FCF Growth
- +118.0%
- 52W High
- $4.90
- 52W Low
- $2.72
- 50D MA
- $3.99
- 200D MA
- $3.59
- Beta
- 0.59
- RSI (14)
- 46
- Avg Volume
- 23.32K
No earnings-call transcripts are available for CCEL yet.
- Free Float
- 50.4%
- Shares Outstanding
- 8.06M
- Float Shares
- 4.06M
of shares held by institutions
12 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sfi Advisors, LLC | 165.30K | 0 |
| Vanguard Capital Management LLC | 164.98K | ▲ 3.45K |
| Vanguard Group Inc | 150.99K | 0 |
| Geode Capital Management, LLC | 46.27K | ▲ 2.66K |
| Vanguard Fiduciary Trust Co | 23.35K | 0 |
| Fmr LLC | 20.00K | ▲ 20.00K |
| Susquehanna International Group, Llp | 14.06K | ▲ 4.05K |
| Blackrock, Inc. | 6.70K | ▼ 7.29K |
| Advisor Group Holdings, Inc. | 2.50K | 0 |
| Morgan Stanley | 605 | ▲ 4 |
| Ubs Group AG | 316 | ▼ 356 |
| Barclays PLC | 14 | ▲ 14 |
Held by 20 ETFs
Biggest fund positions in CCEL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 5, 26 | PORTNOY DAVID | other | 600,191 |
| Aug 5, 26 | PORTNOY DAVID | other | 600,191 |
| May 28, 26 | TAYMANS JILL M | other | 7,500 |
| May 28, 26 | TAYMANS JILL M | other | 7,500 |
| Jan 7, 26 | PORTNOY DAVID | other | 150,000 |
| Jan 7, 26 | PORTNOY DAVID | other | 50,000 |
| Jan 7, 26 | Mikulinsky Oleg | other | 20,000 |
| Jan 7, 26 | Mikulinsky Oleg | other | 10,000 |
| Jan 7, 26 | Portnoy Mark L. | other | 50,000 |
| Jan 7, 26 | Portnoy Mark L. | other | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CCEL coverage
Recent articles, reports, and earnings notes.
No research on CCEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CCEL report →Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results
businesswire.com · Jul 15
Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
businesswire.com · May 8
Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
businesswire.com · Apr 28
Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below 200-Day Moving Average – What’s Next?
defenseworld.net · Apr 21
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
businesswire.com · Apr 14
Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below 200-Day Moving Average – Should You Sell?
defenseworld.net · Apr 3
Cryo-Cell Receives NYSE American Continued Listing Notice
businesswire.com · Mar 12
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
businesswire.com · Feb 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.